Kite, a Gilead Company, today announced that the company’ s Marketing Authorization Application for KTE-X19, an investigational chimeric antigen receptor T cell therapy for the treatment of ...

"Some of our users are facing issues with price updates on the App. We're checking this. For now, please log in to the Kite ...

Kite, a Gilead Company, today announced that it has submitted a Biologics License Application to the U.S. Food and Drug Administration for the investigational chimeric antigen receptor T cell ...

Kite, a Gilead Company (Nasdaq: GILD), today announced that the company’s Marketing Authorization Application (MAA) for KTE-X19, an investigational ch ...

Kite, a Gilead Company (Nasdaq: GILD), today announced that it has submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and ...